Stress, anxiety schizophrenia and neurotrophic factors: the pioneer studies with nerve growth factor

Rivista di Psichiatria

Volumn 44, Issue 2, 2009, Pages 88-94

  Gioiosa, Laura ^a   Iannitelli, Angela ^b   Aloe, Luigi ^a  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antipsychotic drugs; Anxiety; Neurotrophins; NGF; Psychiatric disorders; Schizophrenia; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CHLORPROMAZINE; CHOLINE ACETYLTRANSFERASE; CLOZAPINE; HALOPERIDOL; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; NEUROTROPHIN; OLANZAPINE; PROTEIN TYROSINE KINASE A; QUETIAPINE; RISPERIDONE;

ADRENERGIC SYSTEM; AGGRESSION; ALZHEIMER DISEASE; ANXIETY DISORDER; BEHAVIOR; BLOOD; BLOOD PRESSURE; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; EMOTION; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; MENTAL DISEASE; MENTAL STRESS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NEUROGENIC TUMOR; NEUROPATHOLOGY; NOCICEPTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; TREATMENT INDICATION; TUMOR CELL; WEIGHT GAIN;

ANIMALS; ANXIETY; HUMANS; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 67449167861     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Barde YA: The nerve growth factor family. Progress in Growth Factor Research, 1990,2,237-248.
2. Aloe L, Alleva E, De Simone R: Changes of NGF level in mouse hypothalamus following intermale aggressive behaviour: biological and immunohistochemical evidence. Behavioural Brain Research, 1990,39,53-61.
3. Aloe, Alleva, Bohm, Levi-Montalcini: Aggressive behavior induces release of nerve growth factor from mouse salivary gland into the bloodstream. Proceedings of the National Academy of Sciences of the USA, 1986,83,6184-6187.
4. Axelrod J, Reisine TD: Stress hormones: their interaction and regulation. Science, 1984,224,452-459.
5. Maestripieri D, De Simone R, Aloe L, Alleva E: Social status and nerve growth factor serum levels after agonistic encounters in mice. Physiology & Behavior, 1990,47,161-164.
6. Aloe L, Bracci-Laudiero L, Alleva E, Lambiase A, Micera A, Tirassa P: Emotional stress induced by parachute jumping enhances blood NGF levels and the distribution of NGF receptors in lymphocytes. Proceedings of the National Academy of Sciences of the USA, 1994,91,10440-10444.
7. Luppi P, Levi-Montalcini R, Bracci-Laudiero L, Bertolini A, Arletti R, Tavernari D, et al.: NGF is released into plasma during human pregnancy: an oxytocin-mediated response? Neurore- port, 1993,4,1063-1065.
8. Aloe L, Tuveri MA, Guerra G, Pinna L, Tirassa P, Micera A, et al.: Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. Alcoholism, Clinical and Experimental Research, 1996,20,462-465.
9. Hadjiconstantinou M, McGuire L, Duchemin AM, Laskowski B, Kiecolt-Glaser J, Glaser R: Changes in plasma nerve growth factor levels in older adults associated with chronic stress. Journal of Neuroimmunology, 2001,116,102-106.
10. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A: Nerve growth factor: from neurotrophin to neurokine. Trends in Neurosciences, 1996,19,514-520.
11. Emanuele E, Politi P, Bianchi M, Minoretti P, Bertona M, Geroldi D: Raised plasma nerve growth factor levels associated with early-stage romantic love. Psychoneuroendocrinology, 2006, 31, 288-294.
12. Jockers-Scherubl MC, Rentzsch J, Danker-Hopfe H, Radzei N, Schurer F, Bahri S, et al.: Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neuroscience Letters, 2006,400,262-26.
13. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Archives of General Psychiatry, 1997, 54, 597-606.
14. Angelucci F, Aloe L, Vasquez PJ, Mathe AA: Mapping the differences in the brain concentration of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in an animal model of depression. Neuroreport, 2000,11,1369-1373.
15. Iannitelli A, Aloe L, Bersani G, Maselli P, Angelucci F, Bracci- Laudiero L, et al.: Seizure-induced serum NGF levels increase after ECT in psychiatric patients: a first pilot study in man. Behavioural Pharmacology, 1995,6,93-94.
16. Bersani G, Iannitelli A, Fiore M, Angelucci F, Aloe L: Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Medical hypotheses, 2000,55, 199-207.
17. Fink M: Neuroendocrinology and ECT: a review of recent developments. Comprehensive Psychiatry, 1980,21,450-459.
18. Duman RS, Malberg J, Thome J: Neural plasticity to stress and antidepressant treatment. Biological Psychiatry, 1999, 46,1181- 1191.
19. Chao MV, Rajagopal R, Lee FS: Neurotrophin signalling in health and disease. Clinical Science (London), 2006, 110, 167- 173.
20. Hellweg R, Lang UE, Nagel M, Baumgartner A: Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Molecular Psychiatry, 2002,7, 604-608.
21. Aloe L, Iannitelli A, Bersani G, Alleva E, Angelucci F, Maselli P, et al.: Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology, 1997,36,65-68.
22. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM: Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacology, Biochemistry and Behavior, 1997,56,131-137.
23. Rapoport JL, Addington AM, Frangou S, Psych MR: The neu- rodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry, 2005,10,434-449.
24. Weinberger D: Cell biology of the hippocampal formation in schizophrenia. Biological Psychiatry, 1999,45,395-402.
25. Decker MJ, Rye DB: Neonatal intermittent hypoxia impairs dopamine signaling and executive functioning. Sleep & Breathing, 2002,6,205.
26. Hulshoff Pol HE, Hoek HW, Susser E, Brown AS, Dingemans A, Schnack HG, et al.: Prenatal exposure to famine and brain morphology in schizophrenia. American Journal of Psychiatry, 2000, 157,1170-1172.
27. Sperner-Unterweger B: Immunological aetiology of major psichiatric disorders: evidence and therapeutic implications. Drugs, 2005,65,1493-1520.
28. Fiore M, Korf J, Antonelli A, Talamini L, Aloe L: Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. Neurotoxicology and Teratology, 2002,24,179- 191.
29. Mobley WC, Rutkowski JL.Tennekoon GI, Gemski J, Buchanan K, Johnston MV: Nerve growth factor increases choline acetyl- transferase activity in developing basal forebrain neurons. Brain Research, 1986,387,53-62.
30. Spillantini MG, Aloe L, Alleva E, De Simone R, Goedert M, Levi-Montalcini R: Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression. Proceedings of the National Academy of Sciences of the USA, 1989, 86,8555-8559.
31. Yuen EC, Mobley WC: Therapeutic potential of neurotrophic factors for neurological disorders. Annals of Neurology, 1996,40, 346-354.
32. Bersani G, Iannitelli A, Maselli P, Pancheri P, Aloe L, Angelucci F, et al.: Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophrenia Research, 1999,37, 201-203.
33. Aloe L, Iannitelli A, Angelucci F, Bersani G, Fiore M: Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders. Behavioural Pharmacology, 2000, 11,235-242.
34. Laviola G, Adriani W, Rea M, Aloe L, Alleva E: Social withdrawal, neophobia, and stereotyped behavior in developing rats exposed to neonatal asphyxia. Psychopharmacology, 2004, 175, 196-205.
35. Talamini LM, Koch T, Ter Horst GJ, Korf J: Methyla- zoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat; parallels with morphological findings in schizophrenia. Brain Research, 1998,789,293-306.
36. Fiore M, Talamini L, Angelucci F, Koch T, Aloe L, Korf J: Prenatal methylazoxymethanol acetate alters behavior and brain NGF levels in young rats: a possible correlation with the development of schizophrenia-like deficits. Neuropharmacology, 1999,38,857-869.
37. Di Fausto V, Fiore M, Aloe L: Exposure in fetus of methylazoxymethanol in the rat alters brain neurotrophins' levels and brain cells' proliferation. Neurotoxicology and Teratology, 2007, 29,273-281.
38. Fiore M, Di Fausto V, Iannitelli A, Aloe L: Clozapine or haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations. Annali dell'Istituto Superiore di Sanita, 2008,44,167-177.
39. Pillai A, Terry AV Jr, Mahadik SP: Differential effects of long- term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophrenia Research, 2006,82,95-106.
40. Hefti F: Development of effective therapy for Alzheimer's disease based on neurotrophic factors. Neurobiology of Aging, 1994,15, S193-S194.
41. Olson L, Backman L, Ebendal T, Eriksdotter-Jonhagen M: Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. Journal of Neurology, 1994,242, S12-S15.
42. Schmelzer CH, Burton LE, Chan WP, Martin E, Gorman C, Canova-Davis E, et al.: Biochemical characterization of recombinant human nerve growth factor. Journal of Neurochemistry, 1992,59,1675-1683.
43. Ueyama T, Hano T, Hamada M, Nishio I, Masuyama Y: New role of nerve growth factor: an inhibitory neuromodulator of adrenergic transmission. Brain Research, 1991,20,559,293-296.
44. Zettler C, Head RJ, Rush RA: Chronic nerve growth factor treatment of normotensive rats. Brain Research, 1991,538,251- 262.
45. Yan Q, Settle SL, Wilkins MR: Hypotension induced by intravascular administration of nerve growth factor in the rat. Clinical Science (London), 1991,80,565-569.
46. Yaeger MJ, Koestner A, Marushige K, Marushige Y: The use of nerve growth factor as a reverse transforming agent for the treatment of neurogenic tumors: in vivo results. Acta Neuropathologica, 1992,83,624-629.
47. Lewin GR, Ritter AM, Mendell LM: Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. The Journal of Neuroscience, 1993,13,2136-2148.
48. Tria MA, Fusco M, Vantini G, Mariot R: Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol, 1994,127,178-183.
49. Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zariet- ti O, Riva MA, et al.: Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Molecular Psychiatry, 2002,7,136-137.
50. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, et al.: Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Annals of Neurology, 2002,51,133-136.
51. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, et al.: A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology, 2003,28,397-401.
52. 52. Ribasés M, Gratacós M, Armengol L, de Cid R, Badia A, Jimenéz L, et al.: Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Molecular Psychiatry, 2003,8,745-751.
53. Sklar P, Gabriel SB, Mclnnis MG, Bennett P, Lim YM. Tsan G, et al.: Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Molecular Psychiatry, 2002,7,579-593.
54. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T: Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proceedings of the National Academy of Sciences of the USA, 1995,92,8856-8860.
55. Desai NS, Rutherford LC, Turrigiano GG: BDNF regulates the intrinsic excitability of cortical neurons. Learn Mem, 1999, 6, 284-291.
56. Parikh V, Evans DR, Khan MM, Mahadik SP: Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schiz Res, 2003,60,117-123.
57. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res, 2002,109,143-148.
58. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al.: Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res, 2002,110,249-257.
59. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al.: Low ' plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biological Psychiatry, 2007,31,78-85.
60. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biological Psychiatry, 2006,59,1116-1127.
61. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS: Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. The Journal of Neuroscience, 2002,22,3251-3261.
62. Hoshaw BA, Malberg JE, Lucki I: Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Research, 2005,1037,204-208.
63. Warner-Schmidt JL, Duman RS: VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proceedings of the National Academy of Sciences of the USA, 2007,104,4647-4652.
64. Linden AM, Vaisanen J, Lakso M, Nawa H, Wong G, Castren E: Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. Journal of Molecular Neuroscience, 2000,14, 27-37.
65. Parikh V, Khan MM, Terry A, Mahadik SP: Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J Psych Res, 2004,38,521-529.
66. Angelucci F, Mathe AA, Aloe L: Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered following haloperidone and risperidone administration. Journal of Neuroscience Research, 2000,60,783-794.
67. Takahashi M, Shirakawa O. Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al.: Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Molecular Psychiatry, 2000,5,293-300.
68. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY: Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neuroscience Letters, 2005, 382, 27-32.
69. Lu XH, Dwyer DS: Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. Journal of Molecular Neuroscience, 2005, 27,43-64.
70. Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA: Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. European Neuropsychopharmacology, 2005,15,311-317.
71. Levi-Montalcini R: The nerve growth factor 35 years later. Science, 1987,237,1154-1162.
72. Terry AV, Jr Parikh V, Gearhart DA, Pillai A, Hohnadel E, Warner S, et al.: Time-dependent effects of haloperidol and ziprasi- done on nerve growth factor, cholinergic neurons, and spatial learning in rats. The Journal of Pharmacology and Experimental Therapeutics, 2006,318,709-724.